logo

For the Inventor, By the Inventor

San Antonio, TX, United States of America

Manuel A Riquelme

USPTO Granted Patents = 7 

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal7 out of 5,450 
 
The University of Texas System
 patents

Years Active: 2018-2024

Loading Chart...
7 patents (USPTO):Explore Patents
1. 12162937 - Methods of treating an inflammatory disorder by administering an antibody which binds to a connexin CX43 hemichannel (2024-12-10),
2. 11912762 - Method of treating osteoarthritis by administering an anti-connexin 43 antibody (2024-02-27),
3. 11912758 - Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel (2024-02-27),
4. 11208479 - CX43 hemichannel antibodies and methods of use (2021-12-28),
5. 10889637 - Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies (2021-01-12),
6. 10633442 - Antibodies to connexin 43 (Cx43) hemichannels and methods of use thereof to inhibit Cx43 hemichannel opening (2020-04-28),
7. 9914775 - Methods for treating inflammatory disorders or cancer metastasis by administering antibodies to connexin 43 (Cx43) hemichannels (2018-03-13),

Title: Innovations of Manuel A Riquelme

Introduction

Manuel A Riquelme is a prominent inventor based in San Antonio, Texas. He has made significant contributions to the field of medical research, particularly in the treatment of inflammatory disorders and cancer. With a total of seven patents to his name, Riquelme's work has the potential to impact various therapeutic approaches.

Latest Patents

Riquelme's latest patents include innovative methods for treating inflammatory disorders by administering antibodies that bind to connexin CX43 hemichannels. He has developed methods for identifying compounds that positively regulate connexin 43 hemichannels. Additionally, he has patented methods for treating metastasis, including inhibiting bone cancer metastasis, through the use of antibodies that bind to connexin 43 (Cx43) hemichannels. His research also encompasses antibodies that can either inhibit or activate channel opening, providing new avenues for cancer detection and treatment. Furthermore, Riquelme's work includes methods for treating inflammatory diseases, such as osteoarthritis, and neurological injuries, like spinal cord injuries, using antibodies that modulate Cx43 channel activity.

Career Highlights

Manuel A Riquelme is affiliated with the University of Texas System, where he continues to advance his research and innovation. His work is characterized by a strong focus on the therapeutic potential of connexin 43 hemichannels, which are crucial in various physiological processes.

Collaborations

Riquelme collaborates with esteemed colleagues, including Jean X Jiang and Sumin Gu, to further enhance the impact of his research. Their combined expertise contributes to the development of groundbreaking solutions in the medical field.

Conclusion

Manuel A Riquelme's innovative work in the realm of medical research showcases his dedication to improving treatment options for inflammatory disorders and cancer. His patents reflect a commitment to advancing scientific knowledge and therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…